Compare UHAL & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHAL | GKOS |
|---|---|---|
| Founded | 1945 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 9.7B |
| IPO Year | 1994 | 2015 |
| Metric | UHAL | GKOS |
|---|---|---|
| Price | $55.57 | $178.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | $87.67 | ★ $199.31 |
| AVG Volume (30 Days) | 116.7K | ★ 877.8K |
| Earning Date | 11-04-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,037,819,000.00 | $507,442,000.00 |
| Revenue This Year | $4.24 | $36.30 |
| Revenue Next Year | $5.34 | $23.25 |
| P/E Ratio | $78.63 | ★ N/A |
| Revenue Growth | 3.59 | ★ 32.33 |
| 52 Week Low | $41.95 | $73.16 |
| 52 Week High | $76.45 | $191.62 |
| Indicator | UHAL | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 32.62 | 62.28 |
| Support Level | $54.92 | $175.04 |
| Resistance Level | $59.19 | $186.99 |
| Average True Range (ATR) | 1.57 | 7.56 |
| MACD | 0.10 | 1.90 |
| Stochastic Oscillator | 6.66 | 96.59 |
U-Haul Holding Co is an American moving truck, trailer, and self-storage rental company. The company also provides moving boxes, packing supplies, LPG (propane) refills, trailer hitch and wiring installation, storage container rentals, and other services. It has three reportable segments Moving and Storage, Property and Casualty Insurance, and Life Insurance. The majority of its revenue comes from the Moving and Storage segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.